✉news HealthMedicine first seen 4 d ago, last 3 d ago, peak #29
Zepbound sales jump 49% to $5.35 billion as prices fall
Original: Zepbound Sales Climb 49% to $5.35 Billion as Lilly Sells More Weight-Loss Medicine at Lower Prices
Eli Lilly reported that quarterly sales of its weight-loss drug Zepbound rose 49% to $5.35 billion. The company attributed the growth to higher prescription volumes, achieved even as it cut prices to expand access to the GLP-1 treatment. The figures underscore surging demand for obesity medications, with Lilly competing against Novo Nordisk's Wegovy in one of the fastest-growing corners of the pharmaceutical market.
Why now: Eli Lilly's earnings show the weight-loss drug market booming, with volume growth offsetting lower prices.
Rank over time, top of the chart is #1. 4 snapshots from 4 d ago to 3 d ago.
Evidence
- Zepbound Sales Climb 49% to $5.35 Billion as Lilly Sells More Weight-Loss Medicine at Lower Prices · Medical Daily
API: https://socialmediatrends-api.osmike.com/v1/trends/4552129